Exchange: NASDAQ·Updated 06:05 PM EDT
News
all
press releases
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to...
Business Wire
More News
OMER Stock Gains 4% — CMS Green-Lights $287K Add-On Payments For Transplant Drug
Starting October 1, hospitals can receive up to about $287,000 more from Medicare for each qualifying patient for Yartemlea, Omeros said.
Stocktwits
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA
Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA (narsoplimab-wuug) under the Fiscal Year (FY) 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule...
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz...
PR Newswire
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights
H.C. Wainwright reiterated its ‘Buy’ rating on Omeros after AstraZeneca's Phase 3 setback in HSCT-TMA, saying that the outcome improves Yartemlea's competitive positioning.
Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PR Newswire NEW YORK, July 23, 2026 NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz...
PR Newswire
Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return
Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return...
Yahoo! Finance: News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz...
PR Newswire
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
Key PointsHeartflow uses artificial intelligence to transform coronary imaging into actionable diagnostic data for heart disease...
Nasdaq News: Markets
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation (Omeros or the Company) (NASDAQ: OMER) for violations of the securities laws.The investigation focuses on whether the Company issued false...
Business Wire

Advertisement|Remove ads.